7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Osteoarthritis, Hip D015207 4 associated lipids
Wounds and Injuries D014947 20 associated lipids
Vitamin D Deficiency D014808 13 associated lipids
Vision Disorders D014786 10 associated lipids
Vascular Diseases D014652 16 associated lipids
Urologic Neoplasms D014571 2 associated lipids
Uremia D014511 33 associated lipids
Tooth Resorption D014091 1 associated lipids
Tooth Mobility D014086 2 associated lipids
Tooth Migration D014085 2 associated lipids
Tinnitus D014012 4 associated lipids
Thyroid Neoplasms D013964 33 associated lipids
Thyroid Diseases D013959 8 associated lipids
Thinness D013851 11 associated lipids
Temporomandibular Joint Disorders D013705 4 associated lipids
Takayasu Arteritis D013625 3 associated lipids
Synovitis, Pigmented Villonodular D013586 1 associated lipids
Synovitis D013585 15 associated lipids
Stomatitis D013280 14 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Sclerosis D012598 5 associated lipids
Scleroderma, Systemic D012595 16 associated lipids
Osteosarcoma D012516 50 associated lipids
Sarcoma, Ewing D012512 2 associated lipids
Rupture, Spontaneous D012422 1 associated lipids
Root Resorption D012391 2 associated lipids
Rheumatic Diseases D012216 7 associated lipids
Rheumatic Fever D012213 1 associated lipids
Radicular Cyst D011842 2 associated lipids
Prosthesis Failure D011475 1 associated lipids
Prostatic Neoplasms D011471 126 associated lipids
Progeria D011371 3 associated lipids
Prenatal Exposure Delayed Effects D011297 2 associated lipids
Pregnancy Complications, Hematologic D011250 11 associated lipids
Prediabetic State D011236 1 associated lipids
Polycythemia Vera D011087 13 associated lipids
Polycystic Ovary Syndrome D011085 14 associated lipids
Periostitis D010522 1 associated lipids
Aggressive Periodontitis D010520 8 associated lipids
Periodontitis D010518 22 associated lipids
Periodontal Pocket D010514 9 associated lipids
Periodontal Diseases D010510 15 associated lipids
Familial Mediterranean Fever D010505 12 associated lipids
Pericardial Effusion D010490 2 associated lipids
Periapical Periodontitis D010485 6 associated lipids
Periapical Granuloma D010484 3 associated lipids
Periapical Diseases D010483 4 associated lipids
Paraneoplastic Syndromes D010257 4 associated lipids
Respirovirus Infections D010253 3 associated lipids
Pancreatic Neoplasms D010190 77 associated lipids
Otosclerosis D010040 2 associated lipids
Osteosclerosis D010026 2 associated lipids
Osteoporosis D010024 12 associated lipids
Osteopetrosis D010022 1 associated lipids
Osteonecrosis D010020 5 associated lipids
Osteolysis, Essential D010015 1 associated lipids
Osteolysis D010014 8 associated lipids
Osteoarthritis D010003 4 associated lipids
Osteitis Deformans D010001 3 associated lipids
Osteitis D010000 10 associated lipids
Ossification, Heterotopic D009999 2 associated lipids
Obesity, Morbid D009767 8 associated lipids
Obesity D009765 29 associated lipids
Neuroblastoma D009447 66 associated lipids
Nerve Degeneration D009410 53 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Neoplastic Syndromes, Hereditary D009386 1 associated lipids
Neoplasms, Experimental D009374 10 associated lipids
Neoplasm Invasiveness D009361 23 associated lipids
Myocardial Infarction D009203 21 associated lipids
Cardiomyopathies D009202 10 associated lipids
Musculoskeletal Diseases D009140 2 associated lipids
Multiple Myeloma D009101 13 associated lipids
Mucocutaneous Lymph Node Syndrome D009080 9 associated lipids
Fluorosis, Dental D009050 1 associated lipids
Mitral Valve Stenosis D008946 3 associated lipids
Mitral Valve Insufficiency D008944 4 associated lipids
Measles D008457 3 associated lipids
Mandibular Injuries D008338 1 associated lipids
Mandibular Diseases D008336 5 associated lipids
Malocclusion, Angle Class I D008311 1 associated lipids
Malocclusion D008310 3 associated lipids
Macular Degeneration D008268 5 associated lipids
Lymphocytosis D008218 2 associated lipids
Lymphatic Metastasis D008207 10 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Lung Neoplasms D008175 171 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Leukemia D007938 74 associated lipids
Legg-Calve-Perthes Disease D007873 1 associated lipids
Labyrinthitis D007762 2 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Kidney Diseases D007674 29 associated lipids
Jaw, Edentulous, Partially D007576 1 associated lipids
Jaw, Edentulous D007575 1 associated lipids
Jaw Diseases D007571 4 associated lipids
Insulin Resistance D007333 99 associated lipids
Inflammation D007249 119 associated lipids
Hypothyroidism D007037 32 associated lipids
Hypocalcemia D006996 12 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Leach RJ et al. The genetics of Paget's disease of the bone. 2001 J. Clin. Endocrinol. Metab. pmid:11231972
Luger NM et al. Osteoprotegerin diminishes advanced bone cancer pain. 2001 Cancer Res. pmid:11358823
Haynes DR et al. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. 2001 Rheumatology (Oxford) pmid:11426018
Szulc P et al. Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. 2001 J. Clin. Endocrinol. Metab. pmid:11443182
Sakiyama H et al. Establishment and characterization of macrophage-like cell lines expressing osteoclast-specific markers. 2001 J. Bone Miner. Metab. pmid:11448014
Choi Y et al. Osteoclastogenesis is enhanced by activated B cells but suppressed by activated CD8(+) T cells. 2001 Eur. J. Immunol. pmid:11449372
Kanzaki H et al. Dual regulation of osteoclast differentiation by periodontal ligament cells through RANKL stimulation and OPG inhibition. 2001 J. Dent. Res. pmid:11379890
Hein GE [Pathophysiology of bone loss in rheumatic diseases--do bone markers help in monitoring?]. 2001 Z Rheumatol pmid:11383046
Morony S et al. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. 2001 Cancer Res. pmid:11389072
Kim KJ et al. Osteoprotegerin inhibits in vitro mouse osteoclast formation induced by joint fluid from failed total hip arthroplasty. 2001 J. Biomed. Mater. Res. pmid:11410897
Abu-Amer Y IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB. 2001 J. Clin. Invest. pmid:11390419
Kon T et al. Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing. 2001 J. Bone Miner. Res. pmid:11393777
Fazzalari NL et al. The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis. 2001 J. Bone Miner. Res. pmid:11393778
Bekker PJ et al. The effect of a single dose of osteoprotegerin in postmenopausal women. 2001 J. Bone Miner. Res. pmid:11204435
Kikuchi T et al. Gene expression of osteoclast differentiation factor is induced by lipopolysaccharide in mouse osteoblasts via Toll-like receptors. 2001 J. Immunol. pmid:11207318
O'Brien EA et al. Osteoprotegerin is produced when prostaglandin synthesis is inhibited causing osteoclasts to detach from the surface of mouse parietal bone and attach to the endocranial membrane. 2001 Bone pmid:11182380
Zhang YH et al. Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. 2001 J. Biol. Chem. pmid:11032840
Thirunavukkarasu K et al. Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. 2001 J. Biol. Chem. pmid:11451955
Yun TJ et al. Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. 2001 J. Immunol. pmid:11160187
Stejskal D et al. Osteoprotegerin, RANK, RANKL. 2001 Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub pmid:12426773
Stejskal D et al. Osteoprotegerin and bone density. 2001 Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub pmid:12426776
Takemura M et al. Relationship between osteoprotegerin/osteoclastogenesis inhibitory factor concentration in synovial fluid and disease severity in individuals with osteoarthritis of the knee. 2001 Metab. Clin. Exp. pmid:11172466
Gravallese EM et al. The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption. 2001 Arthritis Res. pmid:11178122
Makiishi-Shimobayashi C et al. Interleukin-18 up-regulates osteoprotegerin expression in stromal/osteoblastic cells. 2001 Biochem. Biophys. Res. Commun. pmid:11181055
Lories RJ and Luyten FP Osteoprotegerin and osteoprotegerin-ligand balance: a new paradigm in bone metabolism providing new therapeutic targets. 2001 Clin. Rheumatol. pmid:11254237
Wan M et al. Transcriptional mechanisms of bone morphogenetic protein-induced osteoprotegrin gene expression. 2001 J. Biol. Chem. pmid:11139569
Browner WS et al. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. 2001 J. Clin. Endocrinol. Metab. pmid:11158021
Hofbauer LC and Heufelder AE [Osteoprotegerin ligand and osteoprotegerin: new concepts of the pathogenesis and therapy of metabolic bone diseases]. 2001 Dtsch. Med. Wochenschr. pmid:11233883
Bolon B et al. Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis. 2001 Mol. Ther. pmid:11237676
Yano K et al. Immunological study on circulating murine osteoprotegerin/osteoclastogenesis inhibitory factor (OPG/OCIF): possible role of OPG/OCIF in the prevention of osteoporosis in pregnancy. 2001 Biochem. Biophys. Res. Commun. pmid:11594776
Brown JM et al. Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. 2001 Clin. Cancer Res. pmid:11595685
Price PA et al. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. 2001 Arterioscler. Thromb. Vasc. Biol. pmid:11597934
Nemec K and Schubert-Zsilavecz M [Future therapies for metabolic bone diseases. New concepts and targets]. 2001 Pharm Unserer Zeit pmid:11715689
Kuntz KA et al. An immunohistochemical study of osteoprotegerin in the human dental pulp. 2001 J Endod pmid:11716077
Hofbauer LC and Schoppet M Serum measurement of osteoprotegerin--clinical relevance and potential applications. 2001 Eur. J. Endocrinol. pmid:11720890
Ueland T et al. Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess--possible role in bone homeostasis. 2001 Eur. J. Endocrinol. pmid:11720891
Chikazu D et al. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors. 2001 J. Bone Miner. Res. pmid:11697804
Khosla S Minireview: the OPG/RANKL/RANK system. 2001 Endocrinology pmid:11713196
Seidel C et al. Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. 2001 Blood pmid:11568016
Fukagawa M et al. Skeletal resistance to pth as a basic abnormality underlying uremic bone diseases. 2001 Am. J. Kidney Dis. pmid:11576943
Sato T et al. Osteoprotegerin levels before and after renal transplantation. 2001 Am. J. Kidney Dis. pmid:11576949
Feuerherm AJ et al. Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis. 2001 Scand. J. Rheumatol. pmid:11578019
Sakai E et al. Characterization of phagosomal subpopulations along endocytic routes in osteoclasts and macrophages. 2001 J. Biochem. pmid:11726283
Quinn JM et al. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions. 2001 J. Bone Miner. Res. pmid:11585342
Choi SJ et al. Osteoclast inhibitory peptide 2 inhibits osteoclast formation via its C-terminal fragment. 2001 J. Bone Miner. Res. pmid:11585344
Miyamoto T et al. Bifurcation of osteoclasts and dendritic cells from common progenitors. 2001 Blood pmid:11588053
Bateman TA et al. Osteoprotegerin ameliorates sciatic nerve crush induced bone loss. 2001 J. Orthop. Res. pmid:11518255
Myoung H et al. Effects of a bisphosphonate on the expression of bone specific genes after autogenous free bone grafting in rats. 2001 J. Periodont. Res. pmid:11519698
Haynes DR et al. The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis. 2001 J Bone Joint Surg Br pmid:11521937
Hofbauer LC and Schoppet M Osteoprotegerin: a link between osteoporosis and arterial calcification? 2001 Lancet pmid:11498208
Sakai A et al. 1alpha-Hydroxyvitamin D3 suppresses trabecular bone resorption by inhibiting osteoclastogenic potential in bone marrow cells after ovariectomy in mice. 2001 J. Bone Miner. Metab. pmid:11498729
Ikeda T et al. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones. 2001 J. Bone Miner. Res. pmid:11499864
Thomas GP et al. Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts. 2001 J. Endocrinol. pmid:11479141
Allan GF et al. Induction of the progesterone receptor gene in estrogen target cells monitored by branched DNA signal amplification. 2001 Steroids pmid:11546554
Feige U Osteoprotegerin. 2001 Ann. Rheum. Dis. pmid:11890662
Lindberg MK et al. Estrogen receptor alpha, but not estrogen receptor beta, is involved in the regulation of the OPG/RANKL (osteoprotegerin/receptor activator of NF-kappa B ligand) ratio and serum interleukin-6 in male mice. 2001 J. Endocrinol. pmid:11739008
Giuliani N et al. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. 2001 Blood pmid:11739153
Croucher PI et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. 2001 Blood pmid:11739154
Dhore CR et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. 2001 Arterioscler. Thromb. Vasc. Biol. pmid:11742876
Ramalho AC et al. Effect of oestradiol on cytokine production in immortalized human marrow stromal cell lines. 2001 Cytokine pmid:11792122
Yano K et al. Synovial cells from a patient with rheumatoid arthritis produce osteoclastogenesis inhibitory factor/osteoprotegerin: reciprocal regulation of the production by inflammatory cytokines and basic fibroblast growth factor. 2001 J. Bone Miner. Metab. pmid:11685652
Kawahara N et al. Two novel cucurbitacins, neocucurbitacins A and B, from the Brazilian folk medicine "Buchinha" (Luffa operculata) and their effect on PEBP2alphaA and OCIF gene expression in a human osteoblast-like Saos-2 cell line. 2001 Chem. Pharm. Bull. pmid:11605678
Boissy P et al. RANKL induces formation of avian osteoclasts from macrophages but not from macrophage polykaryons. 2001 Biochem. Biophys. Res. Commun. pmid:11606048
Wise GE et al. Effects of dexamethasone on tooth eruption in rats: differences in incisor and molar eruption. 2001 Clin Anat pmid:11301468
Atkins GJ et al. Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. 2001 Bone pmid:11336917
Komine M et al. Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor kappaB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture. 2001 Bone pmid:11344046
Chen D et al. ELISA methodology for detection of modified osteoprotegerin in clinical studies. 2001 Clin. Chem. pmid:11274028
Collin-Osdoby P et al. Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. 2001 J. Biol. Chem. pmid:11274143
Brown JM et al. Osteoprotegerin and rank ligand expression in prostate cancer. 2001 Urology pmid:11306358
Yan T et al. Regulation of osteoclastogenesis and RANK expression by TGF-beta1. 2001 Aug 1-9 J. Cell. Biochem. pmid:11573248
Rosa-Rañal M et al. [New paradigms in the regulation of bone metabolism]. 2001 Jul-Aug Rev. Invest. Clin. pmid:11599485
Whyte MP et al. Osteoprotegerin deficiency and juvenile Paget's disease. 2002 N. Engl. J. Med. pmid:12124406
Krane SM Genetic control of bone remodeling--insights from a rare disease. 2002 N. Engl. J. Med. pmid:12124412
Ziolkowska M et al. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. 2002 Arthritis Rheum. pmid:12124857
Campagnuolo G et al. Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis. 2002 Arthritis Rheum. pmid:12124878
Sakata M et al. Osteoprotegerin levels increased by interleukin-1beta in human periodontal ligament cells are suppressed through prostaglandin E(2) synthesized de novo. 2002 Cytokine pmid:12126649
Petersson M et al. Oxytocin stimulates proliferation of human osteoblast-like cells. 2002 Peptides pmid:12126740
Tsuda E [Osteoclastogenesis inhibitory factor (OCIF)/OPG (a novel therapeutic candidate for the treatment of metabolic bone diseases)]. 2002 Nippon Rinsho pmid:11979969
Koshihara Y [Recent progress of bone cell culture system (review)]. 2002 Nippon Rinsho pmid:11979973
Khosla S et al. Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. 2002 J. Clin. Endocrinol. Metab. pmid:11932280
Kanematsu M et al. Vector-averaged gravity regulates gene expression of receptor activator of NF-kappaB (RANK) ligand and osteoprotegerin in bone marrow stromal cells via cyclic AMP/protein kinase A pathway. 2002 Bone pmid:11934645
Li X et al. Effects of prostaglandin E2 on gene expression in primary osteoblastic cells from prostaglandin receptor knockout mice. 2002 Bone pmid:11934647
Sasaki N et al. Changes in osteoprotegerin and markers of bone metabolism during glucocorticoid treatment in patients with chronic glomerulonephritis. 2002 Bone pmid:12052453
Palenzuela L et al. Familial expansile osteolysis in a large Spanish kindred resulting from an insertion mutation in the TNFRSF11A gene. 2002 J. Med. Genet. pmid:12362049
Roodman GD Role of the bone marrow microenvironment in multiple myeloma. 2002 J. Bone Miner. Res. pmid:12412796
Hegedus D et al. Decreased bone density, elevated serum osteoprotegerin, and beta-cross-laps in Wilson disease. 2002 J. Bone Miner. Res. pmid:12412803
Zhao S et al. MLO-Y4 osteocyte-like cells support osteoclast formation and activation. 2002 J. Bone Miner. Res. pmid:12412815
Hu Y and Yu S Gene expression of osteoprotegerin and osteoclast differentiation factor in giant cell tumor. 2002 Zhonghua Bing Li Xue Za Zhi pmid:12419159
Sandor M et al. A novel polyethylene depot device for the study of PLGA and P(FASA) microspheres in vitro and in vivo. 2002 Biomaterials pmid:12219832
Shiotani A et al. Regulation of osteoclast differentiation and function by receptor activator of NFkB ligand and osteoprotegerin. 2002 Anat. Rec. pmid:12221720
Faucheux C et al. Nuclear localization of type I parathyroid hormone/parathyroid hormone-related protein receptors in deer antler osteoclasts: evidence for parathyroid hormone-related protein and receptor activator of NF-kappaB-dependent effects on osteoclast formation in regenerating mammalian bone. 2002 J. Bone Miner. Res. pmid:11874237
Kazama JJ et al. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. 2002 Am. J. Kidney Dis. pmid:11877571
Haas M et al. Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients. 2002 Am. J. Kidney Dis. pmid:11877577
Goater JJ et al. Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis. 2002 J. Orthop. Res. pmid:11918293
Roux S et al. RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma. 2002 Br. J. Haematol. pmid:11918537
Gravallese EM Bone destruction in arthritis. 2002 Ann. Rheum. Dis. pmid:12379632
Spyrou P et al. Cytokine release by osteoblast-like cells cultured on implant discs of varying alloy compositions. 2002 Clin Oral Implants Res pmid:12519337
Berenson JR Advances in the biology and treatment of myeloma bone disease. 2002 Semin. Oncol. pmid:12520479
Woo KM et al. Osteoprotegerin is present on the membrane of osteoclasts isolated from mouse long bones. 2002 Exp. Mol. Med. pmid:12526098
Bengtsson AK and Ryan EJ Immune function of the decoy receptor osteoprotegerin. 2002 Crit. Rev. Immunol. pmid:12498383

Table of Content